Professor Roger is a Consultant Nephrologist and Director at the Renal Unit, Gosford Hospital, Gosford, Australia.
He trained initially at Westmead Hospital in Sydney, then researched at St Bartholomew’s Hospital, London, subsequently receiving his Doctorate of Medicine degree from the University of New South Wales, Australia.
Professor Roger now has over 30 years’ experience researching anaemia and the role of iron in patients with chronic kidney disease. He lectures widely in this field and has been an invited lecturer at numerous national and international congresses and meetings. He has also participated in a number of advisory boards, where he has shared his expertise in the management of anaemia and iron therapy.
He has contributed to a number of clinical trials assessing new anaemia treatments and the role of iron in patients with chronic kidney disease, both through his role as Principle Investigator and as an active Steering Committee member. In addition, he is also a member of several medical associations, including the Australian and New Zealand Society of Nephrology, the International Society of Nephrology.
Lastly, Professor Roger has authored or co-authored over 90 journal articles, including papers the NEJM, JAMA, KI, NDT and AJKD and has contributed to the development of national and international guidelines including Caring for Australians with Renal Insufficiency (CARI Guidelines): Target Haemoglobin and Iron and the 2008 Kidney Disease: Improving Global Outcomes (KDIGO) guideline.
Dr. Lisa M. Guay-Woodford is the McGehee Joyce Professor of Pediatrics at the Children’s National Medical Center (CNMC), a pediatric nephrologist, and an internationally-recognized investigator whose research focuses on identifying clinical and genetic factors involved in the pathogenesis of inherited renal disorders, most notably autosomal recessive polycystic kidney disease (ARPKD). Her laboratory has identified the disease-causing genes in several mouse models of recessive polycystic kidney disease and her group participated in the identification of the human ARPKD gene as part of the ARPKD Consortium. In addition, her laboratory was the first to identify a candidate modifier gene for recessive polycystic kidney disease. Dr. Guay-Woodford has over 140 peer-reviewed publications based on research performed in her own laboratory or as a member of several national and international consortia. She has directed the NIDDK P30-funded Hepato-Renal Fibrocystic Disease Research and Translational Core Center, initially established at the University of Alabama at Birmingham in 2005, and continues to serve as co-Director since moving to CNMC in 2012. Her research program has been funded by the NIH, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and the Polycystic Kidney Disease Foundation. In 2009, Dr. Guay-Woodford was awarded the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease, given by the PKD Foundation and the International Society of Nephrology.
In addition to her investigative work, Dr. Guay-Woodford has established and serves as Director of the CNMC Inherited Renal Disorders Program. She is the Director of the Center for Translational Science, as well as Director of the Clinical and Translational Science Institute at Children’s National Medical Center (CTSI-CN), which is funded by the NIH CTSA program. She serves on several editorial boards for journals in her field. She has been a permanent member and Chair of the NIH Cellular and Molecular Biology of the Kidney Study Section. She is the Past President of the Society for Pediatric Research and Councilor for the International Pediatric Nephrology Association. She has served as a Board of Trustee member for the Polycystic Kidney Disease Foundation as well as the Association of Clinical and Translational Science. She currently serves as a member of the National Institute of Diabetes and Digestive and Kidney Diseases Advisory Council.
Dr Andrea Viecelli is a Senior Lecturer at the Faculty of Medicine, University of Queensland and nephrologist at Princess Alexandra Hospital in Brisbane, Australia. She completed her PhD on strategies to improve vascular access outcomes in patients on haemodialysis through the University of Queensland in 2019. She is a clinical trialist of the Australasian Kidney Trials Network and a lead investigator of the FAVOURED study, an international, multicentre randomised controlled trial of fish oil and aspirin for preventing arteriovenous fistula failure. As a coordinating committee member of the global Standardised outcomes in Nephrology (SONG) initiative, she is leading an international collaborative study (VALID) to validate a standardised core outcome measures for vascular access function. Her research focus is in clinical trials, meta-analyses, and qualitative research in patient-important outcomes. She is an academic editor for PLOS ONE and reviewer for several international high-impact journals. She has published over 30 peer-reviewed articles, 5 book chapters and received numerous awards, including a Kidney Health Australia Clinical Science Award and a Young Investigator Award at the Australian and New Zealand Society of Nephrology Annual Scientific Meeting in 2016 and 2017, and two Young Investigator Award at the ERA-EDTA congress in 2017 and 2018, respectively.
Dr.Sunita Bavanandan graduated from the University of Queensland Australia in December, 1991. She obtained her qualifications as a Member of the Royal College of Physicians United Kingdom in 1997 and became a Fellow of the Royal College of Physicians Edinburgh in 2007. From 2003-2004 she obtained further training at the Leicester General Hospital, United Kingdom. Special interests are in Chronic Kidney Disease, Hypertension, Diabetic Kidney Disease and Peritoneal Dialysis.
She has been a member of several Malaysian Guidelines Development Committees including CPG on Management of Hypertension ( 3rd to 5th editions), CPG on Management of Chronic Kidney Disease in Adults ( 1st and 2nd editions) and CPG for the Management of Heart Failure 2019.
She contributes as an editor/author for chapters in the Malaysian Dialysis & Transplant Registry and the Malaysian Registry of Renal Biopsy. She is a Member of the Southeast Asia Glomerulonephritis Network and is involved in setting up the regional Southeast Asian PD registry (PROMISE) .
She is the current President of the Malaysian Society of Nephrology and is the Head of the Department of Nephrology, Hospital Kuala Lumpur, Malaysia .
Carol Pollock is an academic nephrologist with over 330 publications in basic research and clinical medicine, with an H index of 61 and over 18,750 citations. She is an inaugural Fellow of the Australian Academy of Health and Medical Sciences (2015), was conferred a Vice Chancellors Award for Excellence in Research Supervision (2012) and recognised as a ‘Distinguished Professor’ by the University of Sydney (2012). She was the 2014 recipient of the Ministerial Award for Excellence in Cardiovascular Research. She was Scientific Chairman of the 2013 World Congress of Nephrology, held in Hong Kong. She is Chair of Kidney Health Australia, Deputy Chair of the Board of the Australian Organ, Tissue and Transplant Authority; Chair of the NSW Cardiovascular Research Network and inaugural Chair and then co-chair of the Research Advisory Committee of the Australian and New Zealand Society of Nephrology. She was appointed to NHMRC Council by Minister Greg Hunt in 2018. Health leadership roles include inaugural Chair of the NSW Agency for Clinical Innovation, immediate past Chair of the NSW Clinical Excellence Commission, remaining as a director of both organisations till April 2016. She was Chair of the Northern Sydney Local Health District Board since its inception in 2011 till Dec 2016, was appointed to the Board of the NSW Bureau of Health Information in April 2016 and assumed Chairmanship of the Bureau in November 2016. She is the current Convenor of the NSW Council of Board Chairs of Local Health Districts and Specialty Networks. She is on the scientific advisory committee of Australian Biotech Company Pharmaxis Pty Ltd, is a Director of Certa Therapeutics and a clinical advisor to Quantium Health. In November 2018 she was made an Ambassador of Business Events Sydney.
Patrick (Paddy) Mark is Professor of Nephrology and Honorary Consultant Nephrologist at the Glasgow Renal and Transplant Unit based at the Queen Elizabeth University Hospital Glasgow. He was appointed as Clinical Senior Lecturer in 2011 following clinical training in Medicine and Nephrology combined with a Clinical Lecturer post between 2006-2011. He was promoted to Reader in 2015 and to Professor in 2018. He leads the United Kingdom Cardio-Renal Clinical Study Group, as part of the United Kingdom Kidney Research Consortium. He is the Chief Scientist Office Scotland Clinical Lead for Renal Research. His PhD, awarded the Bellahouston Medal for outstanding thesis by medical graduate, was funded by a British Heart Foundation Junior Clinical Fellowship. He graduated in Medicine in 1999 as Brunton Medallist awarded to the highest achieving student that year.